Vumedi Discloses $104M Series B for Physician AI Learning
A timestamp gives Vumedi a useful place in the argument over AI and medical knowledge. When its software finds a specialist's explanation, the physician can go back to the moment it came from, hear the surrounding discussion and decide how much of the answer survives in context.
The Oakland, California physician learning company disclosed a $104M Series B investment from Oak HC/FT alongside expanded AI capabilities on November 10, 2026. Both participants describe an investment already supporting the business. The announcement connects that capital to a practical ambition: making accumulated clinical teaching easier to find and use while keeping the person doing the teaching within reach.
What Vumedi disclosed about its Series B
Vumedi's November 10 announcement says the Series B capital has gone toward talent, research and development, product development and outreach. Oak HC/FT separately confirms the $104M investment in its account of the company's expanded AI tools. Neither statement establishes a new November closing date, so the disclosure should be read alongside the product progress it describes.
The identity of the investor helps explain the commercial direction. Oak HC/FT's investment rationale focuses on helping physicians understand how experienced peers apply medical advances. That places Vumedi in the work between the arrival of new evidence and a clinician's ability to understand it well enough to use it appropriately.
Vumedi identifies Roman Giverts as its founder and CEO. Its current leadership page lists Ram Ramaswamy as CTO, responsible for engineering, AI, data platforms and product infrastructure, alongside Chief Education Officer Desirae Hazen. Those responsibilities belong together in this product: finding a relevant passage depends on both the software and the quality of the material being searched.
An answer that sends the reader into the explanation
Vumedi describes a library containing more than 100,000 physician-led videos and nearly 5,000 podcast episodes across more than 21 specialties. Its AI lets clinicians ask questions, locate specialist perspectives and compare approaches, then navigate to the relevant point in the recording. The source remains part of the experience after the answer appears.
That design gives the physician several decisions to make. Is this specialist describing the same circumstances? What qualifications surround the statement? Does another expert reach the problem from a different direction? A summary can help a reader get oriented, while the recording preserves more of the reasoning needed to judge whether the comparison is useful.
The commercial asset, in this reading, includes the existing teaching and the relationships that bring specialists to the platform. Better retrieval can make a previously recorded explanation useful to someone who would never have found the full talk. The AI layer can therefore change how much of the archive gets used, even before the company records another minute of content.
For an education team, that creates work beyond adding a search box. Explanations have to be organized and presented so that a quick entry point still leads to an intelligible lesson. A physician arriving halfway through a recording needs enough surrounding context to understand what the speaker is discussing; the product's source navigation makes that return possible.
What the engagement figures can tell us
Vumedi reports that more than 150,000 NPI-verified clinicians have used its AI tools since their launch less than a year before the announcement. The company also reports more than 1M interactions. Those figures describe adoption of the learning tools, with the population defined more narrowly than every visitor or registered member of the broader community.
The company says AI users spend 3.5 times more time on the platform than nonusers. That comparison is interesting for an education business because faster retrieval might have been expected to shorten a visit. One possible interpretation is that finding relevant material encourages further learning, although the published comparison cannot establish that the software caused the difference between the groups.
Clinical outcomes require a separate evidence base. Time spent learning and the number of interactions can help describe engagement; neither metric tells a reader how a particular patient fared. Keeping those questions distinct lets the usage data remain useful without making it carry a medical claim it was never designed to answer.
The other audience for physician education
Vumedi also works with life sciences companies seeking to help physicians understand emerging treatments. Its partnership offering sits beside the clinician community, creating a business relationship around the movement of specialist knowledge. The same explanation can matter to the doctor trying to understand a treatment and the organization trying to make that treatment understood.
That arrangement puts educational credibility inside the economics of the platform. The physician still needs a useful account of the evidence and its application. A commercial partner may value access to that attention, but the attention depends on clinicians continuing to regard the teaching as worth their time.
Vumedi's timestamp feature is relevant to this relationship because it keeps inspection available after retrieval. The physician can return to the speaker, follow the discussion and explore the reasoning around the selected passage. For a platform bringing education and commercial audiences together, that continuing access to context is a consequential product choice.
Where the capital meets the education work
Oak HC/FT cofounder and managing partner Andrew Adams lists Vumedi among his board involvements. The investment brings a healthcare-focused capital partner into a company whose education, engineering and commercial teams all depend on the same relationship with physicians. Each team has a different job, but each needs the learning experience to remain useful after the first answer.
Vumedi says it will continue investing in AI and product development. As more of the library becomes searchable, a recording can acquire another audience long after the original presentation. The work continues at that moment of arrival: a clinician follows a timestamp, listens to the surrounding explanation and decides which question to ask the specialist next.
Healthcare AI funding, last 30 days
DevCuration's funding database tracked 25 Healthcare AI rounds totaling $6.5B in disclosed capital over the past 30 days. Recent deals we covered:
- ODAIA Raises $15M Series C for Pharma Commercial IntelligenceSeries C · $15M · Nov 20
- Isomorphic Labs Raises $5B Series C for AI Drug DesignSeries C · $5B · Nov 18
- TestDynamics Secures $9M to Expand Imaging AI EvaluationSeries A · $9M · Nov 17
- Betterness Raises $1M to Expand Miami Wellness NetworksSeed Extension · $1M · Nov 16
- Knit Health Raises $35M Series A for Clinical AI DeploymentSeries A · $35M · Nov 16
Frequently Asked Questions
How can physicians inspect the source behind a Vumedi AI answer?
Vumedi says clinicians can navigate to time-stamped passages in the specialist videos or podcasts behind an answer. That lets a physician hear the surrounding explanation and compare perspectives rather than relying on the summary alone.
Why does the November 10 announcement differ from a new Series B closing?
Vumedi and Oak HC/FT describe a $104M Series B investment already supporting the company. November 10, 2026 is the disclosure and AI expansion announcement date; the reviewed statements do not establish the exact financing closing date.
What do Vumedi’s AI engagement figures establish?
Vumedi reports more than 150,000 NPI-verified clinicians have used its AI tools and that those users spend more time on the platform than nonusers. These company-reported observations describe learning activity, not a causal study or evidence of improved patient outcomes.
How do life sciences companies fit into Vumedi’s education business?
Vumedi works with life sciences companies seeking to help physicians understand emerging treatments. The relationship makes useful, credible specialist education commercially relevant while physicians still need to assess the evidence and context for themselves.
Where the Money Moved
The intelligence briefing of the innovation economy. Funding, M&A, debt and fund closes, read as market signal rather than deal announcements.
Subscribe to Where the Money Moved



